TPOXX (tecovirimat) from SIGA Technologies is a unique small-molecule drug. In 2018, it became the first drug to win an FDA indication for smallpox. While smallpox was eradicated around 1980s, governments across the world have worried that the variola virus that causes the disease could provide the basis for bioweapons.
The U.S. maintains a stockpile of 1.7 million oral doses of the drug as part of the Strategic National Stockpile.